September 5, 2024 Health 0 Comments How should family spillover effects be measured in HTA? – Healthcare Economist A paper by Campbell et al. (2024) provides some guidance. The authors developed a series of recommendations based on ... Read More
September 5, 2024 Health 0 Comments What is the right sample size for a qualitative interview study? – Healthcare Economist The answer to this question, of course, depends on your specific research question. However, it is helpful to review ... Read More
September 2, 2024 Employee Benefits 0 Comments Health care for workers – Healthcare Economist On this Labor Day, how is healthcare evolving for workers and firms? First, healthcare spending is on the rise, with costs increasing more than ... Read More
August 26, 2024 Academic Articles 0 Comments How to use the RE-AIM framework to evaluate public health interventions – Healthcare Economist The RE-AIM framework developed by Glasgow et al. (1999) has five evaluation components. Reach: share of people from a ... Read More
August 22, 2024 Economics - General 0 Comments What are the potential productivity impacts of new medications that treat Medicare beneficiaries? – Healthcare Economist One key aspect of many medications is that they not only help people feel better, but often these medications ... Read More
August 21, 2024 Dynamic cost-effectiveness 0 Comments Impact of genericization on drug prices and treatment value across 8 countries – Healthcare Economist An interesting study from Miquel Serra-Burriel et al. (2024) examines the impact of genericization on drug prices across 8 ... Read More
August 15, 2024 Current Events 0 Comments Medicare Drug Price Negotiation leads to 38% to 79% price decrease – Healthcare Economist Medicare drug price negotiation is here. The maximum fair prices (MFP) set by Medicare lead to discounts between 38% and 79%. In fact, the ... Read More
August 6, 2024 Cancer 0 Comments Should we extrapolate survival using ‘cure’ models? – Healthcare Economist Clinical trials are short, but the benefits of many drugs lasts months or even years beyond the duration of these trials. To quantify the ... Read More
August 2, 2024 Concentration index 0 Comments Health and wealth – Healthcare Economist Are wealthier people healthier? If so, how strong is this relationship? Does it vary across countries? That is what a paper by Kyriopoulos et ... Read More
July 31, 2024 Adverse Event 0 Comments Methods for Including Adverse Events in Economic Evaluations – Healthcare Economist That is the title of a great review paper by Salah Ghabri, Dalia Dawoud and Michael Drummond. They discuss that guidance on the incorporation ... Read More